Principi Tiziana, Pantanetti Simona, Catani Francesca, Elisei Daniele, Gabbanelli Vincenzo, Pelaia Paolo, Leoni Pietro
Intensive Care Unit, University Hospital, Torrette, via Conca, 60020 Ancona, Italy.
Intensive Care Med. 2004 Jan;30(1):147-50. doi: 10.1007/s00134-003-2056-9. Epub 2003 Oct 31.
To compare the efficacy of early administration of noninvasive continuous positive airway pressure (nCPAP) delivered by the helmet vs. face mask to treat hematological malignancy patients with fever, pulmonary infiltrates, and hypoxemic acute respiratory failure.
Prospective clinical study with historical matched controls in the hematology department of a university hospital.
Seventeen hematological malignancy patients with hypoxemic acute respiratory failure defined as: moderate to severe dyspnea, tachypnea (>30-35 breaths/min), use of accessory muscles and paradoxical abdominal motion, and PaO2/FIO2 ratio less than 200. Each patient was treated with nCPAP by helmet outside the ICU in the hematological ward. Arterial oxygen saturation, heart rate, respiratory rate, and blood pressure were monitored to identify early nCPAP failure. Seventeen historical-matched controls treated in the same department with face mask CPAP were selected as control population; matching criteria were age, sex, diagnosis, and PaO2/FIO2 ratio. Primary end-points were improvement in gas exchanges and the need for endotracheal intubation.
Oxygenation improved in all patients after nCPAP. No patient failed helmet nCPAP because of intolerance while eigh patients in the mask group did so. nCPAP could be applied continuously for a longer period of time in the helmet group (28.44+/-0.20 vs. 7.5+/-0.45 h).
Early nCPAP with helmet improves oxygenation in selected immunosuppressed patients with hypoxemic acute respiratory failure. Tolerance of helmet nCPAP seems better than that of nCPAP delivered by mask.
比较头盔式无创持续气道正压通气(nCPAP)与面罩式无创持续气道正压通气早期应用于治疗血液系统恶性肿瘤伴发热、肺部浸润及低氧性急性呼吸衰竭患者的疗效。
在一所大学医院血液科进行的前瞻性临床研究,设历史对照。
17例血液系统恶性肿瘤伴低氧性急性呼吸衰竭患者,其定义为:中重度呼吸困难、呼吸急促(>30 - 35次/分钟)、使用辅助呼吸肌及胸腹矛盾运动,且动脉血氧分压/吸入氧分数值(PaO2/FIO2)小于200。每位患者在血液科病房的重症监护室外接受头盔式nCPAP治疗。监测动脉血氧饱和度、心率、呼吸频率及血压,以识别早期nCPAP治疗失败情况。选取同一科室17例采用面罩式CPAP治疗的历史对照患者作为对照人群;匹配标准为年龄、性别、诊断及PaO2/FIO2比值。主要终点为气体交换改善情况及气管插管需求。
所有患者接受nCPAP治疗后氧合均有改善。头盔式nCPAP组无患者因不耐受而治疗失败,而面罩组有8例患者因不耐受治疗失败。头盔组nCPAP可连续应用更长时间(28.44±0.20小时对7.5±0.45小时)。
头盔式早期nCPAP可改善部分免疫抑制的低氧性急性呼吸衰竭患者的氧合。头盔式nCPAP的耐受性似乎优于面罩式nCPAP。